APO RESEARCH · REPORT
Infantile Spasms Therapeutics
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Product & engineering
Understand the product.
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Selected research
Industry Growth & Trends
Global Infantile Spasms Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
According to APO Research, the global Infantile Spasms Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Infantile Spasms Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Infantile Spasms Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Infantile Spasms Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Infantile Spasms Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Infantile Spasms Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Infantile Spasms Therapeutics Market by Company
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals
Infantile Spasms Therapeutics Segment by Type
Oral
Injection
Infantile Spasms Therapeutics Segment by Application
Hospital
Clinic
Other
Infantile Spasms Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Infantile Spasms Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- Mallinckrodt
- H. Lundbeck
- Insys Therapeutics
- Orphelia Pharma
- Valerion Therapeutics
- Catalyst Pharmaceuticals
- Anavex Life Sciences
- Retrophin
- GW Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Infantile Spasms Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Infantile Spasms Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Infantile Spasms Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Infantile Spasms Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Infantile Spasms Therapeutics Market Size (2021-2032)
- 1.5.1 North America Infantile Spasms Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Infantile Spasms Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Infantile Spasms Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Infantile Spasms Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Infantile Spasms Therapeutics Market Size Growth Rate (2021-2032)
2 Infantile Spasms Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Oral
- 2.1.2 Injection
- 2.2 Global Infantile Spasms Therapeutics Market Size by Type
- 2.2.1 Global Infantile Spasms Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Infantile Spasms Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Infantile Spasms Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Infantile Spasms Therapeutics Market Size by Regions
- 2.3.1 North America Infantile Spasms Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Infantile Spasms Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Infantile Spasms Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Infantile Spasms Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Infantile Spasms Therapeutics Market Size Breakdown by Type (2021-2026)
3 Infantile Spasms Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Other
- 3.2 Global Infantile Spasms Therapeutics Market Size by Application
- 3.2.1 Global Infantile Spasms Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Infantile Spasms Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Infantile Spasms Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Infantile Spasms Therapeutics Market Size by Regions
- 3.3.1 North America Infantile Spasms Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Infantile Spasms Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Infantile Spasms Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Infantile Spasms Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Infantile Spasms Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Infantile Spasms Therapeutics Industry Trends
- 4.2 Infantile Spasms Therapeutics Industry Drivers
- 4.3 Infantile Spasms Therapeutics Industry Opportunities and Challenges
- 4.4 Infantile Spasms Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Infantile Spasms Therapeutics Revenue (2021-2026)
- 5.2 Global Infantile Spasms Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Infantile Spasms Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Infantile Spasms Therapeutics Company, Product Type & Application
- 5.5 Global Infantile Spasms Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Infantile Spasms Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Infantile Spasms Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Infantile Spasms Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Mallinckrodt
- 6.1.1 Mallinckrodt Company Information
- 6.1.2 Mallinckrodt Business Overview
- 6.1.3 Mallinckrodt Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
- 6.1.5 Mallinckrodt Recent Developments
- 6.2 H. Lundbeck
- 6.2.1 H. Lundbeck Company Information
- 6.2.2 H. Lundbeck Business Overview
- 6.2.3 H. Lundbeck Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
- 6.2.5 H. Lundbeck Recent Developments
- 6.3 Insys Therapeutics
- 6.3.1 Insys Therapeutics Company Information
- 6.3.2 Insys Therapeutics Business Overview
- 6.3.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 6.3.5 Insys Therapeutics Recent Developments
- 6.4 Orphelia Pharma
- 6.4.1 Orphelia Pharma Company Information
- 6.4.2 Orphelia Pharma Business Overview
- 6.4.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
- 6.4.5 Orphelia Pharma Recent Developments
- 6.5 Valerion Therapeutics
- 6.5.1 Valerion Therapeutics Company Information
- 6.5.2 Valerion Therapeutics Business Overview
- 6.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 6.5.5 Valerion Therapeutics Recent Developments
- 6.6 Catalyst Pharmaceuticals
- 6.6.1 Catalyst Pharmaceuticals Company Information
- 6.6.2 Catalyst Pharmaceuticals Business Overview
- 6.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 6.6.5 Catalyst Pharmaceuticals Recent Developments
- 6.7 Anavex Life Sciences
- 6.7.1 Anavex Life Sciences Company Information
- 6.7.2 Anavex Life Sciences Business Overview
- 6.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
- 6.7.5 Anavex Life Sciences Recent Developments
- 6.8 Retrophin
- 6.8.1 Retrophin Company Information
- 6.8.2 Retrophin Business Overview
- 6.8.3 Retrophin Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
- 6.8.5 Retrophin Recent Developments
- 6.9 GW Pharmaceuticals
- 6.9.1 GW Pharmaceuticals Company Information
- 6.9.2 GW Pharmaceuticals Business Overview
- 6.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 6.9.5 GW Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Infantile Spasms Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Infantile Spasms Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Infantile Spasms Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Infantile Spasms Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Infantile Spasms Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Infantile Spasms Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst